EIDD-2801 is a nucleoside analog, meaning it interferes with the replication of RNA viruses by mimicking the building blocks of RNA. When incorporated into the viral RNA during replication, EIDD-2801 introduces errors that can render the virus nonfunctional and unable to replicate effectively.
Like molnupiravir, EIDD-2801 gained attention during the COVID-19 pandemic as a potential treatment for the disease caused by the SARS-CoV-2 virus. Early studies in cell cultures and animal models showed promising results in reducing viral replication and improving outcomes in infected animals. However, it's important to note that clinical trials and further research are needed to determine its efficacy and safety in humans.
| Technical Parameter | Value |
|---|---|
| Generic Name | EIDD-2801 (2349386-89-4) |
| Indication | Treatment of COVID-19 (Cat FIP Treatment) |
| Country of Origin | China |
| Shipping Method | Air (UPS, FedEx, TNT, EMS) or Sea |
| Shelf Life | 2 years |
| Purity | 99% |
| CAS | 2349386-89-4 |
| COA | Available |
| Molecular Weight | 329.31 g/mol |
| Manufacturer | LongilatBio (China) |
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside
